Exploring the Implementation of Cognitive Screening in First-Episode Psychosis Settings: The CogScreen Implementation Study.

Aim: Accurate and appropriate cognitive screening can significantly enhance early psychosis care, yet no screening tools have been validated for the early psychosis population and little is known about current screening practices, experiences, or factors that may influence implementation. CogScreen is a hybrid type 1 study aiming to validate two promising screening tools with young people with first episode psychosis (primary aim) and to understand the context for implementing cognitive screening in early psychosis settings (secondary aim). This protocol outlines the implementation study, which aims to explore the current practices, acceptability, feasibility and determinants of cognitive screening in early psychosis settings from the perspective of key stakeholders.

Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis.

Background: To evaluate the overall satisfaction, device usability, and injection experience of MS patients self-administering ofatumumab using the Sensoready autoinjector device in the United States (US).

Methods: This US-based, cross-sectional survey study included patients with MS (≥ 18 years) who self-administered ofatumumab using the Sensoready device within the previous 12 months of the survey. Eligible patients were administered a 30-item de novo questionnaire that focused on overall device satisfaction, device usability, convenience/flexibility for travel with the device, user confidence, injection experience, and time to administer the injection.

Barriers and Facilitators of User Engagement With Digital Mental Health Interventions for People With Psychosis or Bipolar Disorder: Systematic Review and Best-Fit Framework Synthesis.

Background: Digital mental health interventions (DMHIs) to monitor and improve the health of people with psychosis or bipolar disorder show promise; however, user engagement is variable, and integrated clinical use is low.

Objective: This prospectively registered systematic review examined barriers and facilitators of clinician and patient engagement with DMHIs, to inform implementation within real-world settings.

Methods: A systematic search of 7 databases identified empirical studies reporting qualitative or quantitative data about factors affecting staff or patient engagement with DMHIs aiming to monitor or improve the mental or physical health of people with psychosis or bipolar disorder.

Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers.

Background: Cladribine tablets (CladT) are a multiple sclerosis (MS) disease-modifying therapy (DMT) with safety and efficacy established in the CLARITY trial and extension. A better understanding of the role of CladT in real-world populations is needed, including the clinical and radiographic trajectories of persons with MS (PwMS) treated with CladT and how CladT compares to other MS DMTs.

Methods: PwMS receiving CladT at 4 tertiary MS centers were identified and characterized.

Positive and negative affect differentially relate to alcohol and cannabis use in LGBTQ+ and cisgender-straight heavy-drinking adults: Results of an ambulatory assessment study.

Objective: Previous research has found that momentary positive affect precedes alcohol use, whereas results have been more mixed for negative affect.

Method: This study replicates and builds upon this literature by using a heavy drinking sample, half lesbian, gay, bisexual, trans, queer/questioning, and other minoritized sexual and gender identities (LGBTQ+) individuals.

Results: This study found that positive affect was related to subsequent alcohol use, but the relation was weaker for LGBTQ+ individuals compared to cisgender-straight individuals.